MOESM18 of Predictive proteomic signatures for response of pancreatic cancer patients receiving chemotherapy

Additional file 18: Figure S7. Concentration ratios of PZ, SHBG and VWF between Good-responders and Limited-responders at baseline by proteomics and ELISA

MOESM1 of Predictive proteomic signatures for response of pancreatic cancer patients receiving chemotherapy

Additional file 1: Table S1. Demographic information of the PDAC patients involved in the proteomic study

MOESM4 of Predictive proteomic signatures for response of pancreatic cancer patients receiving chemotherapy

Additional file 4: Table S3. The HQ peptide list

MOESM5 of Predictive proteomic signatures for response of pancreatic cancer patients receiving chemotherapy

Additional file 5: Figure S2. Histograms for the mass deviations of the HQ peptides

MOESM12 of Predictive proteomic signatures for response of pancreatic cancer patients receiving chemotherapy

Additional file 12: Table S9. The TIC N-linked glycopeptides

MOESM10 of Predictive proteomic signatures for response of pancreatic cancer patients receiving chemotherapy

Additional file 10: Table S7. KEGG pathway analysis of the TID proteins

MOESM13 of Predictive proteomic signatures for response of pancreatic cancer patients receiving chemotherapy

Additional file 13: Figure S4. PCA analysis of glycopeptides

MOESM7 of Predictive proteomic signatures for response of pancreatic cancer patients receiving chemotherapy

Additional file 7: Table S4. The BD proteins between Good-responders and Limited-responders

MOESM14 of Predictive proteomic signatures for response of pancreatic cancer patients receiving chemotherapy

Additional file 14: Table S10. The variant peptides with significant difference (p < 0.05) between Good-responders and Limited-responders

MOESM3 of Predictive proteomic signatures for response of pancreatic cancer patients receiving chemotherapy

Additional file 3: Table S2. Proteins identified in the plasma from the PDAC patients